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Cell-mediated immunity (CMI) is one of the important
effector arms during immunological responses to infection
and vaccine development.Therefore, a key challenge in devel-
oping new vaccines that are effective involves the induction
of optimal memory T cell responses [1].This requires a better
understanding of the mechanisms and signals involved in the
generation and maintenance of the host CMI response.Thus,
a rational strategy should be designed based on crucial factors
such as the level and duration of antigen exposure, the use
of adjuvants that can enhance CMI and antibody response,
and also establishing accurate correlates of protection from
diseases. The papers presented in this special issue focus on
the leveraging knowledge of CMI and its probable role in
novel vaccine strategies.
C. E. Ja¨kel et al. reviewed twenty recent clinical studies
regarding the application of cytokine-induced killer (CIK)
cells for the treatment of gastric, pancreatic, hepatocellular,
and colorectal cancers. They showed that in all studies, CIK
cell therapy was well tolerated and safe as well as superior to
conventional therapies alone, since CIK cells have a favorable
therapeutic effect with non-MHC-restricted tumor targeting
and uncomplicated isolation and cultivation. The clinical
study reviewed here thus provides a promising approach in
cancer therapy.
Since the last decades of cancer research, numerous
approaches have been initiated aiming at activating cytotoxic
immune reactions against tumors. Besides targeting the
adaptive immune system, stimulators of the innate immune
system gained much attention. In this context and resulting
from their strong immune stimulatory capacity, ligands for
Toll-like receptors (TLRs) were extensively studied. In line
with this, two of the research papers deal with those aspects
of TLR ligands that have hitherto not been explored in great
depth. The paper by Naumann et al. explores the physio-
chemical and immunostimulatory properties of RGC100, a
TLR3 agonist, whichmay thus represent a promising adjuvant
for prophylactic and therapeutic vaccination strategies. They
showed that RGC100 has a defined chemical structure and
length and has good solubility and stability as well as induces
CD1c+ DC driven T cell proliferation. Furthermore, S. Stier
et al. clarified the two-sided roles of TLRs expressed by tumor
cells. Utilizing the potential of various TLR ligands, alone
or in combinations, they demonstrated control of tumor
growth and activation of immune cells but also unraveled the
requirement of choosing the right combinations as certain
combinations accelerated the tumor growth. The findings
underscore the rationale for using TLR ligands in can-
cer immunotherapy, preferably together with conventional
chemotherapy, as strongest oncolytic effects were observed
in the presence of a functional immune system. Further,
their studies offer insights for elucidating the exact balance
between pro- and antitumor activities of TLR agonists as
single agents but especially of combinations.
S. L. Yingst et al. raise new questions about the impor-
tance of CD8+ T cells in defense against Brucella infection.
They showed a limited role of CD8+ T cells, as IFN-𝛾
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producers or cytotoxic cells, in secondary immunity to B.
melitensis in contrast to previous studies, focused on B. abor-
tus-induced CD8+ T cell responses. Therefore, the authors
suggest that a vaccine strategy aimed at sensitizing CD8+ T
cells may have limited value, although future investigation is
necessary.
New insights on the interaction between Haemophilus
parasuis and cytokine expression in pigs for better under-
standing Glasser’s disease pathogenesis and effective vaccine
development are described in the paper by R. Frandoloso et
al. In this context, they describe the capability of subunit vac-
cines (NPAPTim and NPAPTit: native proteins with affinity
to porcine transferrin) to dampen the transcription of several
chemokines and cytokines (CCL-2, CXCL-8, IL-1𝛼, IL-1𝛽, IL-
6, IL-10, and TNF-𝛼) directly related to severe inflammation
in systemic and target infection organs of nonimmunized
animals. This highlights that NPAPT antigens might be a
suitable candidate to control Glasser’s disease caused by H.
parasuis Nagasaki strain.
We hope the collection of papers in this special issue will
enrich our readers and researchers with latest information
with respect to wide but important field of cell-mediated
immunity and its relationship with novel vaccine develop-
ment.
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